4-hydrazinylfuro[3,2-c]pyridine | 33007-16-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡啶类
• 英文名称: 4-hydrazinylfuro[3,2-c]pyridine
• 英文别名: furo[3,2-c]pyridin-4-ylhydrazine；Hydrazino-4-furo<3,2-c>pyridin；4-hydrazino-furo[3,2-c]pyridine
• CAS: 33007-16-8
• 化学式: C₇H₇N₃O
• 分子量: 149.152
• InChiKey: AHMJULKWSHOYLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-hydrazinylfuro[3,2-c]pyridine 在 镍 肼 作用下， 生成 4-氨基-呋喃[3,2-c]吡啶
  参考文献：
  名称：

  Bourzat,J.-D.; Bisagni,E., Bulletin de la Societe Chimique de France, 1971, p. 1727 - 1730

  摘要：

  DOI：
• 作为产物：
  描述：

  4,5-二氢-4-氧代呋喃[3,2]吡啶 在 一水合肼 、 三氯氧磷 作用下， 反应 2.0h， 生成 4-hydrazinylfuro[3,2-c]pyridine
  参考文献：
  名称：

  Bourzat,J.-D.; Bisagni,E., Bulletin de la Societe Chimique de France, 1971, p. 1727 - 1730

  摘要：

  DOI：

文献信息

• PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
  申请人：Janssen Biotech, Inc.

  公开号：US20180170909A1

  公开（公告）日：2018-06-21

  Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 5 , G 1 , and G 2 are defined herein.

  揭示了一种通过调节MALT1来治疗受影响的疾病、综合症、症状和疾病的化合物、组合物和方法。这些化合物由以下式（I）表示：其中R1、R2、R3、R4、R5、R6、R5、G1和G2在此处定义。
• [EN] INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12)<br/>[FR] INHIBITEURS DE LA KINASE 12 DÉPENDANTE DE LA CYCLINE (CDK12)
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2023091726A1

  公开（公告）日：2023-05-25

  The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

  本发明提供了抑制一个或多个激酶家族（如丝氨酸/苏氨酸激酶，包括一个或多个CDK蛋白家族，特别是CDK12）的化合物。更具体地说，本发明提供了式 (I) 的 CDK12 抑制剂、其药学上可接受的盐和同位素标记的衍生物、含有该化合物/抑制剂的药物组合物，以及它们的合成方法和用于治疗增殖性疾病（如、膀胱癌、乳腺癌、尤文氏肉瘤、胃癌、胃肠道癌、血癌、肺癌（如小细胞肺癌 (SCLC)）、卵巢癌（如、胰腺癌（如胰腺导管腺癌 (PDAC)）、脑癌（如胶质母细胞瘤）或前列腺癌）。增殖性疾病可以是癌症、良性肿瘤或病理性血管生成，本文所述的任何治疗方法或用途都可以包括诊断患者疾病的步骤。在本发明的其他实施方案中，本文所述的组合物（如化合物、药物组合物和含有它们的试剂盒）用于治疗肌营养不良症（1 型或 2 型）。
• Pyrazole derivatives as MALT1 inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US10954214B2

  公开（公告）日：2021-03-23

  Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.

  所公开的是用于治疗受 MALT1 调节影响的疾病、综合征、病症和失调的化合物、组合物和方法。此类化合物由如下式（I）表示： 其中 R1、R2、R3、R4、R5、R6、R5、G1 和 G2 在此定义。
• [EN] PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLE EN TANT QU'INHIBITEURS DE MALT1
  申请人：JANSSEN BIOTECH INC

  公开号：WO2018119036A1

  公开（公告）日：2018-06-28

  Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.
• Bourzat,J.-D.; Bisagni,E., Bulletin de la Societe Chimique de France, 1971, p. 1727 - 1730
  作者：Bourzat,J.-D.、Bisagni,E.

  DOI：——

  日期：——